Cargando…

Asthma-associated risk for COVID-19 development

The newly described severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for a pandemic (coronavirus disease 2019 [COVID-19]). It is now well established that certain comorbidities define high-risk patients. They include hypertension, diabetes, and coronary artery disease. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Skevaki, Chrysanthi, Karsonova, Antonina, Karaulov, Alexander, Xie, Min, Renz, Harald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Academy of Allergy, Asthma & Immunology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834224/
https://www.ncbi.nlm.nih.gov/pubmed/33002516
http://dx.doi.org/10.1016/j.jaci.2020.09.017
_version_ 1783642234959167488
author Skevaki, Chrysanthi
Karsonova, Antonina
Karaulov, Alexander
Xie, Min
Renz, Harald
author_facet Skevaki, Chrysanthi
Karsonova, Antonina
Karaulov, Alexander
Xie, Min
Renz, Harald
author_sort Skevaki, Chrysanthi
collection PubMed
description The newly described severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for a pandemic (coronavirus disease 2019 [COVID-19]). It is now well established that certain comorbidities define high-risk patients. They include hypertension, diabetes, and coronary artery disease. In contrast, the context with bronchial asthma is controversial and shows marked regional differences. Because asthma is the most prevalent chronic inflammatory lung disease worldwide and SARS-CoV-2 primarily affects the upper and lower airways leading to marked inflammation, the question arises about the possible clinical and pathophysiological association between asthma and SARS-CoV-2/COVID-19. Here, we analyze the global epidemiology of asthma among patients with COVID-19 and propose the concept that patients suffering from different asthma endotypes (type 2 asthma vs non–type 2 asthma) present with a different risk profile in terms of SARS-CoV-2 infection, development of COVID-19, and progression to severe COVID-19 outcomes. This concept may have important implications for future COVID-19 diagnostics and immune-based therapy developments.
format Online
Article
Text
id pubmed-7834224
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Academy of Allergy, Asthma & Immunology
record_format MEDLINE/PubMed
spelling pubmed-78342242021-01-26 Asthma-associated risk for COVID-19 development Skevaki, Chrysanthi Karsonova, Antonina Karaulov, Alexander Xie, Min Renz, Harald J Allergy Clin Immunol Reviews and Feature Article The newly described severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for a pandemic (coronavirus disease 2019 [COVID-19]). It is now well established that certain comorbidities define high-risk patients. They include hypertension, diabetes, and coronary artery disease. In contrast, the context with bronchial asthma is controversial and shows marked regional differences. Because asthma is the most prevalent chronic inflammatory lung disease worldwide and SARS-CoV-2 primarily affects the upper and lower airways leading to marked inflammation, the question arises about the possible clinical and pathophysiological association between asthma and SARS-CoV-2/COVID-19. Here, we analyze the global epidemiology of asthma among patients with COVID-19 and propose the concept that patients suffering from different asthma endotypes (type 2 asthma vs non–type 2 asthma) present with a different risk profile in terms of SARS-CoV-2 infection, development of COVID-19, and progression to severe COVID-19 outcomes. This concept may have important implications for future COVID-19 diagnostics and immune-based therapy developments. American Academy of Allergy, Asthma & Immunology 2020-12 2020-09-28 /pmc/articles/PMC7834224/ /pubmed/33002516 http://dx.doi.org/10.1016/j.jaci.2020.09.017 Text en © 2020 American Academy of Allergy, Asthma & Immunology. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Reviews and Feature Article
Skevaki, Chrysanthi
Karsonova, Antonina
Karaulov, Alexander
Xie, Min
Renz, Harald
Asthma-associated risk for COVID-19 development
title Asthma-associated risk for COVID-19 development
title_full Asthma-associated risk for COVID-19 development
title_fullStr Asthma-associated risk for COVID-19 development
title_full_unstemmed Asthma-associated risk for COVID-19 development
title_short Asthma-associated risk for COVID-19 development
title_sort asthma-associated risk for covid-19 development
topic Reviews and Feature Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834224/
https://www.ncbi.nlm.nih.gov/pubmed/33002516
http://dx.doi.org/10.1016/j.jaci.2020.09.017
work_keys_str_mv AT skevakichrysanthi asthmaassociatedriskforcovid19development
AT karsonovaantonina asthmaassociatedriskforcovid19development
AT karaulovalexander asthmaassociatedriskforcovid19development
AT xiemin asthmaassociatedriskforcovid19development
AT renzharald asthmaassociatedriskforcovid19development